Fusion Pharmaceuticals (Fusion) has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) applications for [225Ac]-FPI-2068 (FPI-2068) and corresponding imaging analogue [111In]-FPI-2107 (FPI-2107).

FPI-2068 is a bispecific targeted alpha therapy (TAT) being jointly developed by Fusion and AstraZeneca under a multi-asset collaboration agreement. The therapy will be assessed in a Phase I trial.

The therapy can deliver actinium-225 to solid tumours that express EGFR and cMET, both of which are validated targets co-expressed in many tumour types including non-small cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer and head and neck squamous cell carcinoma.

Fusion的EGFR/cMet 核素新药，与阿斯利康合作。